Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder

Bipolar Disorders

Volumn 17, Issue 3, 2015, Pages 248-256

  Gildengers, Ariel G ^a   Butters, Meryl A ^a   Aizenstein, Howard J ^a   Marron, Megan M ^b   Emanuel, James ^a   Anderson, Stewart J ^b   Weissfeld, Lisa A ^b   Becker, James T ^a   Lopez, Oscar L ^a   Mulsant, Benoit H ^c   Reynolds, Charles F ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bipolar disorder; Lithium; Neuroprotection

Indexed keywords

LITHIUM; LITHIUM DERIVATIVE; TRANQUILIZER;

ADULT; ARTICLE; BIPOLAR DISORDER; BRAIN SIZE; COGNITION; CONTROLLED STUDY; DRUG EXPOSURE; EDUCATIONAL STATUS; FEMALE; FRACTIONAL ANISOTROPY; GRAY MATTER; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFORMANCE; PRIORITY JOURNAL; TREATMENT DURATION; VASCULAR DISEASE; WHITE MATTER; AGED; ANISOTROPY; BRAIN; CASE CONTROL STUDY; COGNITIVE DEFECT; DIFFUSION TENSOR IMAGING; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PSYCHOLOGY; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANISOTROPY; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; CASE-CONTROL STUDIES; COGNITION; COGNITION DISORDERS; DIFFUSION TENSOR IMAGING; FEMALE; GRAY MATTER; HUMANS; LITHIUM COMPOUNDS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; TIME FACTORS; TREATMENT OUTCOME; WHITE MATTER;

EID: 84928205888     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12260     Document Type: Article

References (62)

1. Merikangas KR, Jin R, He JP et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011; 68: 241-251.
2. Kleinman L, Lowin A, Flood E, Gandhi G, Edgell E, Revicki D. Costs of bipolar disorder. Pharmacoeconomics 2003; 21: 601-622.
3. Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. New York, NY: Oxford, 2007.
4. Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs 2013; 27: 135-153.
5. Tondo L, Baldessarini RJ. Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients. Epidemiol Psichiatr Soc 2009; 18: 179-183.
6. van Erp TG, Thompson PM, Kieseppa T et al. Hippocampal morphology in lithium and non-lithium-treated bipolar I disorder patients, non-bipolar co-twins, and control twins. Hum Brain Mapp 2012; 33: 501-510.
7. Schloesser RJ, Martinowich K, Manji HK. Mood-stabilizing drugs: mechanisms of action. Trends Neurosci 2012; 35: 36-46.
8. Freland L, Beaulieu JM. Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci 2012; 5: 14.
9. Bartzokis G. Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology 2012; 62: 2137-2153.
10. Quiroz JA, Gould TD, Manji HK. Molecular effects of lithium. Mol Interv 2004; 4: 259-272.
11. Moore GJ, Bebchuk JM, Hasanat K et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 2000; 48: 1-8.
12. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. Lancet 2000; 356: 1241-1242.
13. Bachmann RF, Wang Y, Yuan P et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 2009; 12: 805-822.
14. Chen G, Zeng WZ, Yuan PX et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999; 72: 879-882.
15. Diniz BS, Machado-Vieira R, Forlenza OV. Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat 2013; 9: 493-500.
16. Kessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008; 65: 1331-1335.
17. Bearden CE, Woogen M, Glahn DC. Neurocognitive and neuroimaging predictors of clinical outcome in bipolar disorder. Curr Psychiatry Rep 2010; 12: 499-504.
18. Lim CS, Baldessarini RJ, Vieta E, Yucel M, Bora E, Sim K. Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. Neurosci Biobehav Rev 2013; 37: 418-435.
19. Bourne C, Aydemir O, Balanza-Martinez V et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand 2013; 128: 149-162.
20. Kempton MJ, Geddes JR, Ettinger U, Williams SCR, Grasby PM. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry 2008; 65: 1017-1032.
21. Schneider MR, DelBello MP, McNamara RK, Strakowski SM, Adler CM. Neuroprogression in bipolar disorder. Bipolar Disord 2012; 14: 356-374.
22. Moorhead TWJ, McKirdy J, Sussmann JED et al. Progressive gray matter loss in patients with bipolar disorder. Biol Psychiatry 2007; 62: 894-900.
23. Gunning-Dixon FM, Raz N. The cognitive correlates of white matter abnormalities in normal aging: a quantitative review. Neuropsychology 2000; 14: 224-232.
24. Macritchie KA, Lloyd AJ, Bastin ME et al. White matter microstructural abnormalities in euthymic bipolar disorder. Br J Psychiatry 2010; 196: 52-58.
25. Hafeman DM, Chang KD, Garrett AS, Sanders EM, Phillips ML. Effects of medication on neuroimaging findings in bipolar disorder: an updated review. Bipolar Disord 2012; 14: 375-410.
26. Germana C, Kempton MJ, Sarnicola A et al. The effects of lithium and anticonvulsants on brain structure in bipolar disorder. Acta Psychiatr Scand 2010; 122: 481-487.
27. Foland LC, Altshuler LL, Sugar CA et al. Increased volume of the amygdala and hippocampus in bipolar patients treated with lithium. Neuroreport 2008; 19: 221-224.
28. Chew ML, Mulsant BH, Pollock BG et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008; 56: 1333-1341.
29. Wingo AP, Wingo TS, Harvey PD, Baldessarini RJ. Effects of lithium on cognitive performance: a meta-analysis. J Clin Psychiatry 2009; 70: 1588-1597.
30. Thompson PM, Bartzokis G, Hayashi KM et al. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cereb Cortex 2009; 19: 1107-1123.
31. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011; 68: 128-137.
32. Vernon AC, Crum WR, Lerch JP et al. Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology. Biol Psychiatry 2014; 75: 982-990.
33. Vernon AC, Natesan S, Modo M, Kapur S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry 2011; 69: 936-944.
34. Samamé C, Martino DJ, Strejilevich SA. A quantitative review of neurocognition in euthymic late-life bipolar disorder. Bipolar Disord 2013; 15: 633-644.
35. Delaloye C, Moy G, de Bilbao F et al. Longitudinal analysis of cognitive performances and structural brain changes in late-life bipolar disorder. Int J Geriatr Psychiatry 2011; 26: 1309-1318.
36. Delaloye C, de Bilbao F, Moy G et al. Neuroanatomical and neuropsychological features of euthymic patients with bipolar disorder. Am J Geriatr Psychiatry 2009; 17: 1012-1021.
37. Tamashiro JH, Zung S, Zanetti MV et al. Increased rates of white matter hyperintensities in late-onset bipolar disorder. Bipolar Disord 2008; 10: 765-775.
38. Wijeratne C, Sachdev S, Wen W et al. Hippocampal and amygdala volumes in an older bipolar disorder sample. Int Psychogeriatr 2013; 25: 54-60.
39. Beyer JL, Kuchibhatla M, Payne ME et al. Hippocampal volume measurement in older adults with bipolar disorder. Am J Geriatr Psychiatry 2004; 12: 613-620.
40. Farr SA, Yamada KA, Butterfield DA et al. Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology 2008; 149: 2628-2636.
41. Wolf PA, Beiser A, Elias MF, Au R, Vasan RS, Seshadri S. Relation of obesity to cognitive function: importance of central obesity and synergistic influence of concomitant hypertension. The Framingham Heart Study. Curr Alzheimer Res 2007; 4: 111-116.
42. Sabia S, Kivimaki M, Shipley MJ, Marmot MG, Singh-Manoux A. Body mass index over the adult life course and cognition in late midlife: the Whitehall II Cohort Study. Am J Clin Nutr 2009; 89: 601-607.
43. Butters MA, Whyte EM, Nebes RD et al. The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry 2004; 61: 587-595.
44. Bhalla RK, Butters MA, Becker JT et al. Patterns of mild cognitive impairment after treatment of depression in the elderly. Am J Geriatr Psychiatry 2009; 17: 308-316.
45. Reynolds CF III, Butters MA, Lopez O et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry 2011; 68: 51-60.
46. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
47. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
48. Gildengers AG, Mulsant BH, Begley AE et al. A pilot study of standardized treatment in geriatric bipolar disorder. Am J Geriatr Psychiatry 2005; 13: 319-323.
49. Miller MD, Paradis CF, Houck PR et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992; 41: 237-248.
50. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22: 312-318.
51. Gildengers AG, Chisholm D, Butters MA et al. Two-year course of cognitive function and instrumental activities of daily living in older adults with bipolar disorder: evidence for neuroprogression? Psychol Med 2013; 43: 801-811.
52. Rej S, Butters MA, Aizenstein HJ et al. Neuroimaging and neurocognitive abnormalities associated with bipolar disorder in old age. Int J Geriatr Psychiatry 2014; 29: 421-427.
53. Wu M, Rosano C, Butters M et al. A fully automated method for quantifying and localizing white matter hyperintensities on MR images. Psychiatry Res 2006; 148: 133-142.
54. Wu M, Rosano C, Lopez-Garcia P, Carter CS, Aizenstein HJ. Optimum template selection for atlas-based segmentation. Neuroimage 2007; 34: 1612-1618.
55. Mori S, Crain BJ. MRI Atlas of Human White Matter, 1st edn. Boston, MA: Elsevier, 2005.
56. Smith SM, Jenkinson M, Johansen-Berg H et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006; 31: 1487-1505.
57. Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry 2008; 23: 704-711.
58. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011; 198: 351-356.
59. Hampel H, Ewers M, Burger K et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 2009; 70: 922-931.
60. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007; 190: 359-360.
61. Terao T, Nakano H, Inoue Y, Okamoto T, Nakamura J, Iwata N. Lithium and dementia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1125-1128.
62. Leyhe T, Eschweiler GW, Stransky E et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis 2009; 16: 649-656.